GEN released an analysis identifying the top 20 drugs whose key U.S. patents expire between 2026 and 2029, representing roughly $176–230 billion in combined annual sales at risk. The list and accompanying commentary document the scale of upcoming exclusivity losses and how that dynamic is reshaping M&A, R&D prioritization, and life‑cycle management strategies across big pharma. The report links the looming expiries to a surge in strategic transactions—acquisitions and licensing aimed at replenishing pipelines—and provides context on how companies are using deal structures, partnerships, and new modality bets to offset revenue decline. Investors and corporate strategists will view the cliff as a primary driver of consolidation and an incentive for accelerating next‑generation modalities (gene therapy, RNA, ADCs) and platform investments that can create new high‑value franchises before patent losses materialize.